array(63) { ["SERVER_SOFTWARE"]=> string(6) "Apache" ["REQUEST_URI"]=> string(50) "/instituto/idorpost_scientists/daniel-herchenhorn/" ["PHP_PATH"]=> string(24) "/opt/bitnami/php/bin/php" ["FREETDSLOCALES"]=> string(0) "" ["FREETDSCONF"]=> string(0) "" ["OPENSSL_ENGINES"]=> string(31) "/opt/bitnami/common/lib/engines" ["OPENSSL_CONF"]=> string(39) "/opt/bitnami/common/openssl/openssl.cnf" ["SSL_CERT_FILE"]=> string(52) "/opt/bitnami/common/openssl/certs/curl-ca-bundle.crt" ["CURL_CA_BUNDLE"]=> string(52) "/opt/bitnami/common/openssl/certs/curl-ca-bundle.crt" ["LDAPCONF"]=> string(42) "/opt/bitnami/common/etc/openldap/ldap.conf" ["GS_LIB"]=> string(43) "/opt/bitnami/common/share/ghostscript/fonts" ["MAGICK_CODER_MODULE_PATH"]=> string(60) "/opt/bitnami/common/lib/ImageMagick-6.9.8/modules-Q16/coders" ["MAGICK_CONFIGURE_PATH"]=> string(73) "/opt/bitnami/common/lib/ImageMagick-6.9.8/config-Q16:/opt/bitnami/common/" ["MAGICK_HOME"]=> string(19) "/opt/bitnami/common" ["PATH"]=> string(260) "/opt/bitnami/apps/wordpress/bin:/opt/bitnami/varnish/bin:/opt/bitnami/sqlite/bin:/opt/bitnami/php/bin:/opt/bitnami/mysql/bin:/opt/bitnami/letsencrypt/:/opt/bitnami/apache2/bin:/opt/bitnami/common/bin:/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin" ["USER"]=> string(6) "daemon" ["HOME"]=> string(9) "/usr/sbin" ["SCRIPT_NAME"]=> string(10) "/index.php" ["QUERY_STRING"]=> string(0) "" ["REQUEST_METHOD"]=> string(3) "GET" ["SERVER_PROTOCOL"]=> string(8) "HTTP/1.0" ["GATEWAY_INTERFACE"]=> string(7) "CGI/1.1" ["REDIRECT_URL"]=> string(50) "/instituto/idorpost_scientists/daniel-herchenhorn/" ["REMOTE_PORT"]=> string(5) "15133" ["SCRIPT_FILENAME"]=> string(44) "/opt/bitnami/apps/wordpress/htdocs/index.php" ["SERVER_ADMIN"]=> string(15) "[email protected]" ["CONTEXT_DOCUMENT_ROOT"]=> string(34) "/opt/bitnami/apps/wordpress/htdocs" ["CONTEXT_PREFIX"]=> string(0) "" ["REQUEST_SCHEME"]=> string(4) "http" ["DOCUMENT_ROOT"]=> string(34) "/opt/bitnami/apps/wordpress/htdocs" ["REMOTE_ADDR"]=> string(13) "54.232.26.227" ["SERVER_PORT"]=> string(2) "80" ["SERVER_ADDR"]=> string(11) "172.26.1.14" ["SERVER_NAME"]=> string(13) "54.225.48.228" ["SERVER_SIGNATURE"]=> string(0) "" ["LD_LIBRARY_PATH"]=> string(410) "/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/varnish/lib:/opt/bitnami/varnish/lib/varnish:/opt/bitnami/varnish/lib/varnish/vmods:/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/common/lib64" ["HTTP_CF_IPCOUNTRY"]=> string(2) "US" ["HTTP_TRUE_CLIENT_IP"]=> string(14) "44.220.249.141" ["HTTP_CDN_LOOP"]=> string(10) "cloudflare" ["HTTP_CF_CONNECTING_IP"]=> string(14) "44.220.249.141" ["HTTP_ACCEPT_LANGUAGE"]=> string(14) "en-US,en;q=0.5" ["HTTP_ACCEPT"]=> string(63) "text/html,application/xhtml+xml,application/xml;q=0.9,*/*;q=0.8" ["HTTP_USER_AGENT"]=> string(40) "CCBot/2.0 (https://commoncrawl.org/faq/)" ["HTTP_CF_VISITOR"]=> string(22) "{\"scheme\":\"https\"}" ["HTTP_CF_RAY"]=> string(20) "83318cc36cf907b7-GRU" ["HTTP_ACCEPT_ENCODING"]=> string(4) "gzip" ["HTTP_X_AMZN_TRACE_ID"]=> string(40) "Root=1-65750d9f-0eb9c3db3f3647520dd9ff55" ["HTTP_X_FORWARDED_PORT"]=> string(3) "443" ["HTTP_CONNECTION"]=> string(5) "close" ["HTTP_X_FORWARDED_PROTO"]=> string(4) "http" ["HTTP_X_FORWARDED_FOR"]=> string(44) "44.220.249.141, 172.71.16.138, 10.247.46.126" ["HTTP_X_REAL_IP"]=> string(13) "10.247.46.126" ["HTTP_X_FORWARDED_HOST"]=> string(25) "www.rededorsaoluiz.com.br" ["HTTP_HOST"]=> string(13) "54.225.48.228" ["SCRIPT_URI"]=> string(70) "http://54.225.48.228/instituto/idorpost_scientists/daniel-herchenhorn/" ["SCRIPT_URL"]=> string(50) "/instituto/idorpost_scientists/daniel-herchenhorn/" ["REDIRECT_STATUS"]=> string(3) "200" ["REDIRECT_SCRIPT_URI"]=> string(70) "http://54.225.48.228/instituto/idorpost_scientists/daniel-herchenhorn/" ["REDIRECT_SCRIPT_URL"]=> string(50) "/instituto/idorpost_scientists/daniel-herchenhorn/" ["FCGI_ROLE"]=> string(9) "RESPONDER" ["PHP_SELF"]=> string(10) "/index.php" ["REQUEST_TIME_FLOAT"]=> float(1702170015.5322) ["REQUEST_TIME"]=> int(1702170015) }

Daniel Herchenhorn

Daniel Herchenhorn

Dedico-me nos últimos 20 anos, por meio de pesquisas clínicas e estudos translacionais, ao desenvolvimento de novas terapias isoladas ou em combinação, com exploração de biomarcadores em tumores sólidos, em especial, tumores urológicos, de cabeça e pescoço e melanoma maligno. Conto com com um grupo de colegas compostos por uma equipe multi-disciplinar composta por oncologistas, radiooncologistas, médicos nucleares entre outros, que nos auxiliam na condução dos estudos clínicos bem como revisões de literatura. Atualmente, atuo como pesquisador assistente do IDOR, instituto responsável pelas atividades de pesquisa, ensino e inovação da Rede D’Or São Luiz, além de ser Coordenador Científico do Grupo de Oncologia D’Or e Coordenador do Programa de Residência em Oncologia da Oncologia D’Or, Rio de Janeiro.

Palavras-chave: Tumores Urológicos; Câncer de Próstata; Câncer de Cabeça e Pescoço; Melanoma Maligno.

PESQUISA

Doutorado em Oncologia pela USP/SP

Residência Médica em Oncologia Clínica, Instituto Nacional de Câncer

Lancet Oncology Prostate Cancer Committee

ÁREAS DE PESQUISA

INFORMAÇÕES ADICIONAIS

Prêmios e Títulos

Membro Titular Academia de Medicina do Rio de Janeiro - AMRJ, AMRJ

Prêmio Análise Medicina, Análise Editorial

Latin America Research Award, Novartis - USA

Lilly 2001 Pharmacogenomic Award, Eli lilly and Company

Global Young Investigators Award, Glym-Ely Lilly- USA

Publicações Selecionadas

Werutsky G, Maluf FC, Cronemberger EH, Carrera Souza V, Dos Santos Martins SP, Peixoto F, Smaletz O, Schutz F, Herchenhorn D, Santos T, Mavignier Carcano F, Queiroz Muniz D, Nunes Filho PRS, Zaffaroni F, Barrios C, Fay A. The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. BMC Cancer. 2019 May 23;19(1):487. PMID: 31122212; PMCID: PMC6533731.

Maluf F, Soares A, Avanço G, Hada AL, Cardoso APG, Carneiro A, Herchenhorn D, Jardim DLF, Schutz FA, Kater FR, Pereira FMT, Monteiro FSM, Morbeck IAP, Reolon JFN, da Trindade KM, Andrade LMQDS, Nogueira LM, Furoni R, Natel RA, Dos Reis RB, Fogace RN, Souza VC. Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician’s perception according to patient comorbidities. Int Braz J Urol. 2021 Mar-Apr;47(2):359-373. PMID: 33284538; PMCID: PMC7857750.

Maluf FC, Pereira FMT, Silva AG, Dettino ALA, Cardoso APG, Sasse AS, Soares A, Kann AG, Herchenhorn D, Jardim DLF, Cortés DEL, Kater FR, Morbeck IAP, Reolon JFN, Rinck JA Jr, Zarbá JJ, Sade JP, da Trindade KM, Costa LAGA, Dos Santos LV, Maia MC, Siqueira MB, Gillessen S. Consensus on the Treatment and Follow-Up for Metastatic Castration-Resistant Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC). JCO Glob Oncol. 2021 Apr;7:559-571. PMID: 33856891; PMCID: PMC8162971.

Treistman N, Nobre GM, Tramontin MY, da Silva GMW, Herchenhorn D, de Lima Araujo LH, de Andrade FA, Corbo R, Bulzico D, Vaisman F. Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience. Arch Endocrinol Metab. 2021 Nov 3;65(4):411-420. Epub 2021 Apr 29. PMID: 33939907.

Herchenhorn D, Freire V, Oliveira T, Tarouquella J. Sequential therapies for advanced urothelial cancer: Hope meets new challenges. Crit Rev Oncol Hematol. 2021 Apr;160:103248. Epub 2021 Mar 13. PMID: 33727199.

Conteúdo Relacionado
Fale com a gente.